Evidence map›Paper›PMID 38368708›Full record

ArticleMolecular genetics and metabolism2024

Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).

Isabella Peixoto de Barcelos, Sarah Woidill, Francesco Gavazzi, Nicholson B Modesti, Anjana Sevagamoorthy, Adeline Vanderver, Laura Adang

Open access · greenAbstract read
In one paragraph

Article in Molecular genetics and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Rigorous genetic diagnosis review in natural history studies.Orphanet journal of rare diseases · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Isabella Peixoto de BarcelosDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Sarah WoidillDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Francesco GavazziDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nicholson B ModestiDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Anjana SevagamoorthyDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Adeline VanderverDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, usa.
Laura AdangDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, usa. Electronic address: adangl@chop.edu.
Children's Hospital of Philadelphia · US

Funding

Validation of the GMFC-MLDU54NS115052 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI Adeline Lucie Vanderver · 2019 to 2026
$14.3M
Clinical Outcomes in Aicardi Goutières SyndromeU01NS106845 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI VANDERVER, ADELINE LUCIE · 2019 to 2023
$7.5M
Clinical measures in Aicardi Goutieres SyndromeK23NS114113 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI ADANG, LAURA ANN · 2019 to 2023
$947k
NINDS NIH HHS K23 NS114113NINDS NIH HHS U01 NS106845NINDS NIH HHS U54 NS115052
6 · The paper itself

Abstract

objectiveAicardi Goutières Syndrome (AGS) is a genetic interferonopathy associated with multisystemic heterogeneous disease and neurologic dysfunction. AGS includes a broad phenotypic spectrum which is only partially explained by genotype. To better characterize this variability, we will perform a systematic analysis of phenotypic variability in familial cases of AGS.

methodsAmong thirteen families, twenty-six siblings diagnosed with AGS were identified from the Myelin Disorders and Biorepository Project (MDBP) at the Children's Hospital of Philadelphia. Data were collected on the age of onset, genotype, neurologic impairment, and systemic complications. Neurologic impairment was assessed by a disease-specific scale (AGS Severity Scale) at the last available clinical encounter (range: 0-11 representing severe - attenuated phenotypes). The concordance of clinical severity within sibling pairs was categorized based on the difference in AGS Scale (discordant defined as >2-unit difference). The severity classifications were compared between sibling sets and by genotype.

resultsFive genotypes were represented: TREX1 (n = 4 subjects), RNASEH2B (n = 8), SAMHD1 (n = 8) ADAR1 (n = 4), and IFIH1 (n = 2). The older sibling was diagnosed later relative to the younger affected sibling (median age 7.32 years [IQR = 14.1] compared to 1.54 years [IQR = 10.3]). Common presenting neurologic symptoms were tone abnormalities (n = 10/26) and gross motor dysfunction (n = 9/26). Common early systemic complications included dysphagia and chilblains. The overall cohort median AGS severity score at the last encounter was 8, while subjects presenting with symptoms before one year had a median score of 5. The TREX1 cohort presented at the youngest age and with the most severe phenotype on average. AGS scores were discordant for 5 of 13 sibling pairs, most commonly in the SAMHD1 pairs. Microcephaly, feeding tube placement, seizures and earlier onset sibling were associated with lower AGS scores (respectively, Wilcoxon rank sum: p = 0.0001, p < 0.0001, p = 0.0426, and Wilcoxon signed rank: p = 0.0239).

conclusionsIn this systematic analysis of phenotypic variability in familial cases, we found discordance between siblings affected by AGS. Our results underscore the heterogeneity of AGS and suggest factors beyond AGS genotype may affect phenotype. Understanding the critical variables associated with disease onset and severity can guide future therapeutic interventions and clinical monitoring. This report reinforces the need for further studies to uncover potential factors to better understand this phenotypic variability, and consequently identify potential targets for interventions in attempt to change the natural history of the disease.

Indexed as

Autoimmune Diseases of the Nervous SystemExodeoxyribonucleasesGenetic Association StudiesGenotypeNervous System MalformationsPhenotypeSiblingsAdolescentAge of OnsetChildChild, PreschoolFemaleHumansInfantInterferon-Induced Helicase, IFIH1MaleExodeoxyribonucleasesIFIH1 protein, humanInterferon-Induced Helicase, IFIH1Monomeric GTP-Binding ProteinsPhosphoproteinsRibonuclease Hribonuclease HIIRNA-Binding ProteinsSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanthree prime repair exonuclease 1Aicardi Goutières SyndromeDevelopmental delayGenotypeLeukodystrophy

Identifiers

PMID38368708
PMCPMC11431181
OpenAlexW4391782949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.